Cencora, Inc. COR SPX

Q: What is the current share price of Cencora, Inc. (COR)?

As of 2026-07-14 21:23 PDT, Cencora, Inc. (COR) trades at $302.28 on NYSE. Its 52-week range is $252.16 to $373.25.

Q: What is the market capitalisation of COR?

Cencora, Inc. (COR) has a market capitalisation of $58.81B on NYSE.

Q: What is the P/E ratio of COR?

COR trades at a trailing price-to-earnings (P/E) ratio of 23.18. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 16.13.

Q: Does COR pay a dividend?

Cencora, Inc. (COR) currently offers a dividend yield of 0.85%.

Q: What is the return on equity (ROE) of COR?

COR has a return on equity (ROE) of 107.13%. Its return on capital employed (ROCE) is 14.00%.

Q: Is COR a good stock to buy?

This page provides a data-driven analysis of Cencora, Inc. (COR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Distribution · United States

https://www.cencora.com

Company Profile ↓

$302.28

+2.53% 1Y

Mkt Cap$58.81B

P/E23.18

P/B16.13

Div. Yield0.85%

52W High$373.25

52W Low$252.16

Book Value$17.46

EPS (TTM)$13.04

Company Overview

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 107.1%, reflecting efficient use of shareholder capital.

Reasonable Valuation

Trades at a P/E of 23.2, below the sector median of 25.4.

Recent Developments

Sep 2025 Revenue of $321.33B (+9.3% YoY); net profit $1.55B.
Trailing 12 Months Year-on-year growth — revenue +3.8%, earnings +128.3%.
5-Year Trend Long-term compounding — revenue CAGR 9.2%, profit CAGR 6.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	9.22%
1 Year:	3.80%

Compounded Profit Growth

5 Years:	6.88%
1 Year:	128.30%

Stock Price Performance

1 Year:	+2.53%
6 Months:	-9.59%
3 Months:	-5.06%
1 Month:	+7.39%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 41% of range

$252.16 $373.25

Trend Signals

Price vs 50-DMAAbove
Price vs 200-DMABelow
RSI (14)62.18 · Neutral

Price Performance

1M+7.39%

3M-5.06%

6M-9.59%

1Y+2.53%

Valuation vs Sector

P/E of 23.18 is below the sector median of 25.41 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 107.1%.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

23.18

Industry PE

25.41

Forward P/E

15.28

PEG Ratio

0.60

Book Value

$17.46

Price to Book

16.13

P/S

0.17

EV/EBITDA

12.81

Dividend Yield

0.85%

Growth (CAGR)

Revenue 5Y

9.22%

Profit 5Y

6.88%

Revenue (YoY)

3.80%

Earnings (YoY)

128.30%

Profitability & Returns

ROCE

14.00%

ROE

107.13%

ROA

3.49%

Profit Margin

0.78%

Op Margin

1.72%

Gross Margin

3.80%

EPS (Latest Qtr)

$8.40

EPS (TTM)

$13.04

Balance Sheet & Liquidity

Debt/Equity

4.21

Quick Ratio

0.48

Current Ratio

0.95

Debt

$15.09B

Total Assets

$81.65B

Current Assets

Working Capital

Ownership

Promoter Holding

4.23%

Chg in Prom Hold

FII / Inst Holding

98.78%

Chg in FII Hold

0.02%

Financial Snapshot

Enterprise Value

$58.81B

Total Revenue (TTM)

$328.68B

EBITDA

$5.30B

Free Cash Flow

$-318.25M

Operating Cash Flow

$2.28B

Shares Outstanding

194.56M

Gross Margin

3.80%

Payout Ratio

17.62%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	COR Cencora, Inc. SPX	302.28	23.18	$58.81B	0.85%	14.00%	107.13%	9.22%	6.88%
2	LLY Eli Lilly and Company SPX	1,152.54	41.02	$1.03T	0.61%	-	107.46%	7.20%	11.41%
3	JNJ Johnson & Johnson SPX	253.85	29.45	$611.07B	2.23%	14.88%	26.42%	2.43%	4.76%
4	ABBV AbbVie Inc. SPX	244.78	119.40	$432.48B	3.04%	10.47%	-129.24%	1.75%	-29.06%
5	UNH UnitedHealth Group Incorporated SPX	425.19	32.02	$386.13B	2.27%	9.74%	12.18%	10.40%	5.43%
6	MRK Merck & Co., Inc. SPX	120.78	34.02	$298.31B	2.86%	-	18.94%	5.64%	10.01%
7	AZN AstraZeneca PLC NDX	164.50	24.81	$255.12B	1.77%	15.97%	23.48%	9.82%	45.96%
8	TMO Thermo Fisher Scientific Inc. SPX	534.07	29.33	$198.47B	0.40%	8.14%	13.52%	8.81%	12.95%
9	AMGN Amgen Inc. NDXSPX	355.25	24.69	$191.73B	2.84%	18.02%	101.32%	11.77%	5.58%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2015	Jun 2015	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Dec 2021	Mar 2022	Jun 2022	Dec 2022	Mar 2023	Jun 2023	Dec 2023	Mar 2024	Jun 2024	Dec 2024	Mar 2025	Jun 2025	Dec 2025	Mar 2026
Revenue	32.67B	34.23B	35.47B	36.71B	35.70B	36.88B	37.56B	38.17B	37.15B	38.71B	39.12B	40.47B	41.03B	43.14B	43.30B	45.39B	43.32B	45.24B	45.64B	47.86B	47.42B	45.37B	49.24B	52.52B	49.15B	53.41B	59.63B	57.72B	60.06B	62.85B	63.46B	66.95B	72.25B	68.41B	74.24B	81.49B	75.45B	80.66B	85.93B	78.36B
Gross Profit	911.98M	891.46M	973.57M	964.88M	1.08B	1.11B	1.12B	1.04B	1.26B	1.08B	1.17B	1.11B	1.26B	1.21B	1.03B	1.30B	1.42B	1.23B	1.18B	1.23B	1.39B	1.23B	1.35B	1.45B	1.53B	1.89B	2.06B	2.24B	2.02B	2.15B	2.30B	2.26B	2.47B	2.54B	2.41B	2.56B	3.06B	2.91B	3.07B	3.59B
Operating Income	-363.06M	334.18M	538.48M	-178.14M	950.48M	528.63M	224.80M	399.99M	624.98M	170.38M	-135.00M	418.97M	481.42M	389.19M	154.10M	477.82M	47.56M	406.69M	179.84M	263.44M	309.51M	404.83M	-6.11B	547.23M	624.35M	620.73M	644.40M	780.16M	487.30M	633.14M	560.52M	670.13M	822.88M	553.26M	672.48M	706.25M	1.04B	867.65M	760.45M	1.14B
Net Income	-514.11M	213.36M	363.12M	329.64M	603.45M	349.15M	145.69M	247.25M	411.47M	50.35M	-344.59M	861.85M	287.45M	275.81M	233.29M	393.65M	27.14M	301.96M	132.62M	187.64M	960.28M	289.44M	-4.85B	374.85M	435.27M	292.12M	449.11M	548.01M	406.96M	479.75M	435.40M	479.58M	601.50M	420.77M	483.46M	488.60M	717.87M	687.40M	559.65M	1.64B
Diluted EPS	-2.33	0.89	1.56	1.45	2.68	1.55	0.64	1.11	1.86	0.23	-1.58	3.90	1.29	1.25	1.07	1.84	0.13	1.43	0.63	0.90	4.64	1.41	-23.74	1.81	2.10	1.40	2.13	2.59	1.92	2.33	2.13	2.35	2.98	2.09	2.42	2.50	3.68	3.52	2.87	8.40

Profit & Loss (Annual)

Figures in USD.

Metric	Sep 2007	Sep 2008	Sep 2009	Sep 2010	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Revenue	65.67B	70.19B	71.76B	77.78B	78.70B	78.08B	87.96B	119.57B	135.96B	146.85B	153.14B	167.94B	179.59B	189.89B	213.99B	238.59B	262.17B	293.96B	321.33B
Gross Profit	2.22B	2.05B	2.10B	2.33B	2.46B	2.63B	2.51B	2.98B	3.53B	4.27B	4.55B	4.61B	5.14B	5.19B	6.94B	8.30B	8.96B	9.91B	11.48B
Operating Income	788.74M	827.86M	883.75M	1.09B	1.19B	1.30B	898.40M	782.09M	422.22M	1.53B	1.06B	1.44B	1.11B	-5.14B	2.35B	2.37B	2.34B	2.18B	2.63B
Net Income	469.17M	250.56M	503.40M	636.75M	706.62M	718.99M	433.71M	274.23M	-138.16M	1.43B	364.48M	1.66B	855.37M	-3.41B	1.54B	1.70B	1.75B	1.51B	1.55B
Diluted EPS	1.25	0.77	1.66	2.22	2.54	2.80	1.84	1.16	-0.63	6.32	1.64	7.53	4.04	-16.65	7.39	8.04	8.53	7.53	7.96

Balance Sheet (Annual)

Figures in USD.

Metric	Sep 2006	Sep 2007	Sep 2008	Sep 2009	Sep 2010	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Oct 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Total Assets	-	-	12.22B	13.57B	14.43B	14.98B	15.44B	18.92B	21.53B	27.96B	33.64B	35.32B	37.67B	-	39.17B	44.27B	57.34B	56.56B	62.56B	67.10B	76.59B
Total Equity	4.14B	3.10B	2.71B	2.72B	2.95B	2.87B	2.45B	2.31B	1.94B	616.39M	2.13B	2.06B	2.93B	-	2.88B	-1.02B	223.35M	-211.56M	522.00M	645.94M	1.51B
Cash & Equivalents	1.26B	640.20M	878.11M	1.01B	1.66B	1.83B	1.07B	1.23B	1.81B	2.17B	2.74B	2.44B	2.49B	-	3.37B	4.60B	2.55B	3.39B	2.59B	3.13B	4.36B
Long Term Debt	-	-	1.19B	1.18B	1.34B	972.86M	1.40B	1.40B	2.00B	3.49B	3.58B	3.43B	4.16B	400.00M	4.03B	3.62B	6.38B	4.63B	4.15B	3.81B	7.54B
Current Liabilities	-	-	8.17B	9.48B	9.91B	10.88B	11.27B	14.87B	17.25B	21.58B	25.28B	26.82B	27.87B	-	29.58B	33.85B	41.36B	43.48B	48.83B	54.28B	57.82B

Cash Flows (Annual)

Figures in USD.

Metric	Sep 2007	Sep 2008	Sep 2009	Sep 2010	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Operating Cash Flow	1.21B	737.07M	783.76M	1.11B	1.17B	1.31B	788.12M	1.46B	3.92B	3.18B	1.50B	1.41B	2.34B	2.21B	2.67B	2.70B	3.91B	3.48B	3.88B
Investing Cash Flow	-674.44M	163.42M	-148.35M	-184.37M	-212.42M	-947.95M	117.26M	-384.15M	-2.93B	-3.17B	-498.04M	-1.11B	-375.83M	-379.87M	-6.14B	-368.44M	-2.60B	-618.10M	-4.98B
Financing Cash Flow	-1.15B	-662.58M	-504.16M	-275.44M	-787.72M	-1.12B	-740.99M	-502.99M	-632.13M	565.07M	-1.31B	-242.87M	-1.09B	-603.62M	1.95B	-1.75B	-2.22B	-2.33B	2.25B
Capital Expenditure	-111.28M	-137.31M	-145.84M	-176.47M	-156.14M	-133.29M	-202.45M	-264.46M	-231.59M	-464.62M	-466.40M	-336.41M	-310.22M	-369.68M	-438.22M	-496.32M	-458.36M	-487.17M	-667.98M
Free Cash Flow	1.10B	599.76M	637.93M	932.15M	1.01B	1.17B	585.67M	1.20B	3.69B	2.71B	1.04B	1.07B	2.03B	1.84B	2.23B	2.21B	3.45B	3.00B	3.21B
Share Buybacks	1.43B	679.68M	450.35M	470.36M	840.58M	1.16B	484.18M	753.93M	1.86B	2.27B	329.93M	639.24M	674.03M	420.45M	82.15M	483.70M	1.18B	1.49B	435.47M

Ratios (Annual)

Figures in %.

Metric	Sep 2007	Sep 2008	Sep 2009	Sep 2010	Sep 2011	Sep 2012	Sep 2013	Sep 2014	Sep 2015	Sep 2016	Sep 2017	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024	Sep 2025
Gross Margin %	3.4%	2.9%	2.9%	3.0%	3.1%	3.4%	2.9%	2.5%	2.6%	2.9%	3.0%	2.7%	2.9%	2.7%	3.2%	3.5%	3.4%	3.4%	3.6%
Operating Margin %	1.2%	1.2%	1.2%	1.4%	1.5%	1.7%	1.0%	0.7%	0.3%	1.0%	0.7%	0.9%	0.6%	-2.7%	1.1%	1.0%	0.9%	0.7%	0.8%
Net Margin %	0.7%	0.4%	0.7%	0.8%	0.9%	0.9%	0.5%	0.2%	-0.1%	1.0%	0.2%	1.0%	0.5%	-1.8%	0.7%	0.7%	0.7%	0.5%	0.5%
ROE %	15.1%	9.2%	18.5%	21.6%	24.6%	29.3%	18.8%	14.1%	-22.4%	67.1%	17.7%	56.5%	29.7%	334.5%	689.5%	-803.0%	334.3%	233.6%	103.1%
ROCE %	-	20.4%	21.6%	24.1%	29.0%	31.2%	22.2%	18.3%	6.6%	18.3%	12.5%	14.7%	11.6%	-49.3%	14.7%	18.1%	17.1%	17.0%	14.0%

Shareholding Pattern

Insiders

4.23%

Institutions

98.78%

Public Float

103.14%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	10.25%	19.94M	$5.87B
2	Vanguard Capital Management LLC	6.33%	12.31M	$3.62B
3	Vanguard Portfolio Management LLC	4.93%	9.59M	$2.82B
4	State Street Corporation	4.72%	9.19M	$2.70B
5	Price (T.Rowe) Associates Inc	3.76%	7.32M	$2.16B
6	FMR, LLC	3.44%	6.69M	$1.97B
7	T. Rowe Price Investment Management, Inc.	3.24%	6.29M	$1.85B
8	Geode Capital Management, LLC	2.86%	5.57M	$1.64B
9	JPMORGAN CHASE & CO	2.51%	4.89M	$1.44B
10	Wellington Management Group, LLP	2.34%	4.55M	$1.34B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for COR

Google News ue, 14 Jul 2026

Cencora (COR) Following Soft Earnings Is The Stock Starting To Look Undervalued - simplywall.st

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxPak03a0llM1N2cjY1c0E1dXNnMGFwOXZVNUV4eXZIM243Z2x6RWdWZnZjOTZGUURaNTN3bW4xYlJwMHExcmNnUWlVSVgzeTdmOXdKSzNaNXpXdmxmSVZwb2lDeVN2OGN4TGFKU01wM1JjUG5ZLXM1Mnk3eVo1VG4tQXFRY09oVFRmNlVWR0…

Google News Mon, 13 Jul 2026

Health Insurance Providers Stocks Q1 In Review: Cencora (NYSE:COR) Vs Peers - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPcFpBclIwNjhnZDBoTm5aWWp0dlY0UE1fVndranFyM1pLUHdOMFo3TWNBa1ZIMDd4TXpydGpxSTBLY3VQcHBjbnE5M2k3bk5ySE4tbFhjbkpCV0NlVE05d1ZSQ3BMMmtCZTJ6TWI5R0VEcWN1UXhWV2UwUnl5R2YtdmNMa1ozUmlyYm5yV3…

Google News Sun, 12 Jul 2026

The Technical Signals Behind (COR) That Institutions Follow - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPcHhuQ1NMYklkUFlLVUdYQW9VNlVtUkFVZkRUcThaT1NZS0R3ekJmckI1QXBDSHozVWRnZU5xengzZi13cGRxMDM0NFJObVY2WVp2aDZhMENoNEExd0lfVXFiR1plX0JhanRLc3UzYUt1dmdHT3Z1dF9RaXdiTHpnaEhvTVZObVpoUGxPTE…

Google News Mon, 22 Jun 2026

Insider Purchase: Director at $COR Buys 4,000 Shares | COR Stock News - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQX1k2aEk3cEYxZmFFVG1ycGhmeWpnSGlHVXBfZXFhNVY4c1prTlNBczJWNlEwVEJlVFZOTWVDTmFnNTRSdzlrQ08wTnhoLUpfWEhQaFdKU3ZDelBMRWJXWEc3MGJ1dzlnU1FrX2haeGxfay1nRzYxVEVFV1UzSjR4ZURpeWd0NV9VLUhTaG…

Google News hu, 09 Jul 2026

ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge - The Motley Fool

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQYTVLYlo1QkZGZHhpVWlSQXBGTUZTNmtzWWtFSHYxZEotdDJKRmFNTXFQNnVnb0VtdkZqRzJ1NUtfc0VKWlUyRFFJRWgyWHJwZkZmbFY1ZE1hMURONjNJM3N6OXU2WElCWjQ4Nl9GUkJFbHFUeXNZRHo4RlZiQnpUSERKRXhMVE9LY1FGcW…

Google News hu, 18 Jun 2026

COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell? - TradingView

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxPR2pzM1g5b2JiSDd6TklrZ3FEN2dkRnM0Rmc4NE9PUXV0RjBUVnIySzBkQ1g2RmpPLTRxM2VPUnBfQWllNS1ZalZTLTRMSkpRZ0FiTU92aDR5Y3lhbENaaU9PeUJtSTNrWjlxY1ZZbk9PSTZ0ZVNvMjRZRmJrN3ZrRUxxb284WUtXOGlpWl…

COR — Frequently Asked Questions

What is the current share price of Cencora, Inc. (COR)?

As of 2026-07-14 21:23 PDT, Cencora, Inc. (COR) trades at $302.28 on NYSE. Its 52-week range is $252.16 to $373.25.

What is the market capitalisation of COR?

Cencora, Inc. (COR) has a market capitalisation of $58.81B on NYSE.

What is the P/E ratio of COR?

COR trades at a trailing price-to-earnings (P/E) ratio of 23.18. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 16.13.

Does COR pay a dividend?

Cencora, Inc. (COR) currently offers a dividend yield of 0.85%.

What is the return on equity (ROE) of COR?

COR has a return on equity (ROE) of 107.13%. Its return on capital employed (ROCE) is 14.00%.

Is COR a good stock to buy?

This page provides a data-driven analysis of Cencora, Inc. (COR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Cencora, Inc. COR SPX

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Cencora (COR) Following Soft Earnings Is The Stock Starting To Look Undervalued - simplywall.st

Health Insurance Providers Stocks Q1 In Review: Cencora (NYSE:COR) Vs Peers - Yahoo Finance

The Technical Signals Behind (COR) That Institutions Follow - Stock Traders Daily

Insider Purchase: Director at $COR Buys 4,000 Shares | COR Stock News - Quiver Quantitative

ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge - The Motley Fool

COR Stock Down Nearly 18% YTD: Should You Buy, Hold or Sell? - TradingView

COR — Frequently Asked Questions

What is the current share price of Cencora, Inc. (COR)?

What is the market capitalisation of COR?

What is the P/E ratio of COR?

Does COR pay a dividend?

What is the return on equity (ROE) of COR?

Is COR a good stock to buy?

Explore More